We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00531635
Recruitment Status : Unknown
Verified December 2011 by King Faisal Specialist Hospital & Research Center.
Recruitment status was:  Recruiting
First Posted : September 19, 2007
Last Update Posted : December 13, 2011
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center

Brief Summary:
Induction of mixed hemopoietic chimerism in patients using Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA & Mycophenolate Mofetil

Condition or disease Intervention/treatment Phase
Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil Drug: Mycophenolate Mofetil Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil
Study Start Date : July 2002
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : June 2012



Intervention Details:
    Drug: Mycophenolate Mofetil
    Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil


Primary Outcome Measures :
  1. Efficacy [ Time Frame: 2001-2012 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients receiving Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA & Mycophenolate Mofetil.

Exclusion Criteria:

  • Uncontrolled major medical illnesses

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00531635


Contacts
Contact: Mahmoud AlJurf, MD 966-1-4647272 ext 24586 maljurf@kfshrc.edu.sa
Contact: Ed Colcol

Locations
Saudi Arabia
KFSH&RC Recruiting
Riyadh, Saudi Arabia, 11211
Contact: Mahmoud Aljurf, MD    966-1-4647272 ext 24586      
Contact: Ed Colcol    966-1-4647272 ext 38015    colcol@kfshrc.edu.sa   
Principal Investigator: Mahmoud Aljurf, MD         
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Mahmoud Aljurf, MD KFSH&RC

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT00531635     History of Changes
Other Study ID Numbers: RAC#2001-051
First Posted: September 19, 2007    Key Record Dates
Last Update Posted: December 13, 2011
Last Verified: December 2011

Keywords provided by King Faisal Specialist Hospital & Research Center:
Mixed hemopoietic chimerism, Fludarabine, TBI, PBSC, immunosuppression, Mycophenolate Mofetil

Additional relevant MeSH terms:
Fludarabine
Fludarabine phosphate
Mycophenolic Acid
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors